Positive association between high-sensitivity c-reactive protein level and diabetes mellitus among US non-hispanic black adults

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 8, 2008, Pages 455-460

  Shankar, A ^a   Li, J ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Blacks; C reactive protein; CRP; Diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; TREND STUDY; WAIST CIRCUMFERENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OVERWEIGHT; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 54549099181     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1004563     Document Type: Article

References (32)

1. Albert MA, Ridker PM. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? Circulation 2006; 114 (5): e67-e74
2. Doi Y, Kiyohara Y, Kubo M et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005; 28 (10): 2497-2500
3. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51 (4): 1131-1137
4. Duncan BB, Schmidt MI, Pankow JS et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52 (7): 1799-1805
5. Thorand B, Lowel H, Schneider A et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003; 163 (1): 93-99
6. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286 (3): 327-334
7. Barzilay JI, Abraham L, Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50 (10): 2384-2389
8. Freeman DJ, Norrie J, Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002: 51 (5): 1596-1600
9. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004: 53 (3): 693-700
10. Han TS, Sattar N, Williams K, Gonzalez-Vilialpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25 (11): 2016-2021
11. Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003: 52 (3): 812-817
12. Herder C, Peltonen M, Koenig W et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 2006; 55 (8): 2340-2346
13. National Centerfor Health Statistics. NHANES 1999-2002 Survey Questionnaires, Examination Components and Laboratory Components [article online]. Available online from: www cdc gov/nchs/about/major/ nhanes/questexam10_02 htm [Accessed March 15 2007] 2007
14. National Center for Health Statistics. NHANES 1999-2002 addendum to the NHANES III analytic guidelines [article online]. Available online from: www cdc gov/nchs/data/nhanes/guidelines1 pdf [Accessed March 15 2007] 2007
15. National Center for Health Statistics. NHANES 1999-2002 Survey. C-Reactive Protein in Serum By Nephelometry [article online]. Available online from: http://www cdc gov/nchs/data/nhanes/nhanes_01_02/ l11_b_met_c_reactive_protein pdf [Accessed March 15 2007] 2007
16. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003: 107 (3): 499-511
17. Figueiras A, Cadarso-Suarez C. Application of nonparametric models for calculating odds ratios and their confidence intervals for continuous exposures. Am J Epidemiol 2001; 154 (3): 264-275
18. Hastie T, Tibshirani R. Generalized additive models 1st ed. London: Chapman and Hall 1990
19. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116 (7): 1793-1801
20. Visser M, Bouter LM, MacQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282 (22): 2131-2135
21. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985; 153 (1): 9-13
22. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006; 84 (2): 427-433
23. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 2001; 30 (3): 540-546
24. Esposito K, Pontillo A, Di PC et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003: 289 (14): 1799-1804
25. Manns PJ. Williams DP, Snow CM, Wander RC. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Hum Biol 2003; 15 (1): 91 -100
26. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18): 1343-1350
27. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403
28. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87 (2): 563-568
29. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33 (6): 1506-1511
30. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103 (3): 357-362
31. Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286 (15): 1882-1885
32. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107 (9): 1291-1296